Effect of decisive formulation variables on bioencapsulation efficiency and integrity of yeast biocapsules for oral itraconazole delivery

Journal of Microencapsulation

Volumn 28, Issue 4, 2011, Pages 311-322

  Sangwai, Mayur B ^a   Vavia, Pradeep Ratilal ^a  

^a INSTITUTE OF CHEMICAL TECHNOLOGY   (India)

Author keywords

biomaterials; cell encapsulation; controlled delivery

Indexed keywords

ITRACONAZOLE;

ARTICLE; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG FORMULATION; DRUG RELEASE; DRUG SOLUBILITY; DRUG STABILITY; ENCAPSULATION; NONHUMAN; TABLET HARDNESS; TEMPERATURE; YEAST CELL;

ADMINISTRATION, ORAL; ANTIFUNGAL AGENTS; HUMANS; ITRACONAZOLE; SOLUBILITY; YEAST, DRIED;

EID: 79955808447     PISSN: 02652048     EISSN: 14645246     Source Type: Journal    
DOI: 10.3109/02652048.2011.569762     Document Type: Article

References (27)

1. Bishop RP, Nelson G, Lambs J. Microencapsulation in yeast cells. J Microencapsul, 1998;15:761-73. (Pubitemid 28490947)
2. Blanquet S, Marol-Bonnin S, Beyssac E, Pompon D, Renaud M, Alric M. The biodrug concept: An innovative approach to therapy. Trends in Biotechnol, 2001;19:393-400. (Pubitemid 32925032)
3. Ci YX, Zang KS, Gao TY. FTIR study of microbes. Chem J Chinese Univ, 2002;6:1047-9.
4. Dardelle G, Normand V, Steenhoudt M, Bouquerand P, Chevalier M, Baumgartner P. Flavour encapsulation and flavour-release performances of a commercial yeast-based delivery system. Food Hydrocolloids, 2007;21:953-60. (Pubitemid 46400963)
5. Grant SM, Clissold SP. Itraconazole: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses. Drugs, 1989;37:310-44. (Pubitemid 19083614)
6. Folch J, Lees M, Stanley S. A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chemis, 1957;226:497-9.
7. Hong J, Kim J, Song Y, Park J, Kim C. A new self-emulsifying formulation of itraconazole with improved dissolution and oral absorption. J Control Release, 2006;110:332-8. (Pubitemid 41827486)
8. Hausner HH. Friction conditions in a mass of metal powder. Int J Powder Metall, 1967;3:7-13.
9. Jee H, Shin Y, Choi YC, Kim A, Myung GL. Dependent pharmacokinetics of itraconazole after intravenous or oral administration to rats: Intestinal first-pass effect. Antimicrob Agents Chemo, 2004;48:1756-62.
10. Jung J, Yoo S, Lee K, Kim K, Yoon D, Lee K. Enhanced solubility and dissolution rates of itraconazole by a solid dispersion technique. Int J Pharm, 1999;187:209-18. (Pubitemid 29443901)
11. Kasai T, Eguchi T, Ishiwaki N, Kaneshige J, Ozeki T, Yuasa H. Application of acid-treated yeast cell wall (AYC) as a pharmaceutical additive. I. AYC as a novel coating material. Int J Pharm, 2000;204:53-9.
12. Kumar V, Kothari SH, Banker GS. Compression, compaction, and disintegration properties of low crystallinity celluloses produced using different agitation rates during their regeneration from phosphoric acid solutions. AAPS Pharm Sci Tech, 2001;2, article 7.
13. Lipinslki C. Poor aqueous solubility - an industry wide problem in drug discovery. Am Pharm Rev, 2002;5:82-5.
14. Muller RH, Peters K. Nanosuspensions for the formulation of poorly water soluble drugs. I. Preparation by a size reduction technique. Int J Pharm, 1998;160:229-37. (Pubitemid 28083096)
15. Northcote DH, Horne RW. The chemical composition and structure of yeast cell wall. Biochem J, 1952;51:232-6.
16. Peeters J, Neeskens P, Tollenaere JP, Remoortere PV, Brewster M. Characterization of the interaction of 2-hydroxypropyl-cyclodextrin with itraconazole at pH 2, 4 and 7. J Pharm Sci, 2002;91:1414-22.
17. Rabinow BE. Nanosuspensions in drug delivery. Nat Rev Drug Discov, 2004;3:785-96. (Pubitemid 39242830)
18. Rabinowa B, Kipp J, Papadopoulos P, Wong J, Glosson J, Gass J, Sunc C, Wielgos T, White R, Cook C, et al. Itraconazole IV nanosuspension enhances efficacy through altered pharmacokinetics in the rat. Int J Pharm, 2007;339:251-60. (Pubitemid 46977603)
19. Sajbidor J, Certik M, Grego J. Lipid analysis of baker's yeast. J Chrom, 1994;665:191-5.
20. Shangraw RF, Wallace JW, Bowers FM. Morphology and functionality in tablet excipients for direct compression: Part I. Pharm Technol, 1981;5:69-78.
21. Shi GR, Rao LQ, Yu HZ, Xiang H, Pen GP, Long S, Yang C. Yeast-cell-based microencapsulation of chlorogenic acid as a water-soluble antioxidant. J Food Eng, 2007;80:1060-7. (Pubitemid 46107712)
22. Shi GR, Raoa L, Yu H, Xiang H, Yang H, Ji R. Stabilization and encapsulation of photosensitive resveratrol within yeast cells. Int J Pharm, 2008;349:83-93. (Pubitemid 350299698)
23. Smith ID, Waters DG. Determination of residual solvent levels in bulk pharmaceuticals by capillary gas chromatography. Analyst, 1991;116:1327-31.
24. Yang W, Tam J, Miller DA, Zhouc J, McConville JT, Johnstonb KP, Williams RO. High bioavailability from nebulized itraconazole nanoparticle dispersions with biocompatible stabilizers. Int J Pharm, 2008;361:177-88.
25. Yilwoong Y, Yoon HJ, Kim BO, Shim M, Kim S, Hwang S, Seo MH. A mixed polymeric micellar formulation of itraconazole: Characteristics, toxicity and pharmacokinetics. J Control Release, 2007;117:59-67. (Pubitemid 46161866)
26. Yuasa H, Kaneshige J, Ozeki T, Kasai T, Eguchi T, Ishiwaki N. Application of acid-treated yeast cell wall (AYC) as a pharmaceutical additive. II: Effects of curing on the medicine release from AYC-coated tablets. Int J Pharm, 2000;209:69-77.
27. Wang X, Michoel A, Mooter G. Solid state characteristics of ternary solid dispersions composed of PVP VA64, Myrj 52 and itraconazole. Int J Pharm, 2005;303:54-61. (Pubitemid 41318021)